Syncona Shs GBP (GB:SYNC) has released an update.Don't Miss our Black Friday Offers:Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top StocksMake ...

"Slingshot represents an opportunity to bridge the gap between academic innovation and clinical development of a novel ...

Syncona Shs GBP (GB:SYNC) has released an update. Syncona’s portfolio company, Autolus Therapeutics, has received FDA ...

Syncona noted that the approval is set against the backdrop of poor outcomes for patients with r/r B-ALL, an aggressive blood ...

The upfront cash consideration in the transaction with Syncona is to consist of $0.34 per share of AGTC common stock (including common stock underlying restricted stock units and in-the-money ...

Syncona Ltd (SYNC.L) said that its portfolio company Autolus Therapeutics announced that the U.S. Food and Drug Administration has ...

Syncona Shs GBP (GB:SYNC) has released an update. Syncona Limited, a prominent life science investor, has repurchased 200,000 of its own ordinary shares as part of its ongoing share buyback ...

Syncona Ltd, (“Syncona”) a leading life science investor focused on creating, building and scaling global leaders in life science, today announces that it has launched a new portfolio company ...

Syncona said the performance was mostly driven by a decline in Autolus Therapeutics PLC share price and a weaker US dollar, and was partially offset by valuation uplifts from private portfolio company ...

Slingshot, the Syncona Accelerator, is focused on accumulating and developing a pipeline of early-stage programmes identified from academia · Slingshot's first programme, Apini, is a small ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.

(RTTNews) - Syncona Ltd (SYNC.L) said that its portfolio company Autolus Therapeutics announced that the U.S. Food and Drug Administration has granted marketing approval for AUCATZYL (obe-cel ...